68Ga-PSMA-11 PET-directed Radioligand Therapy in Metastatic Liver Cancer
This study is testing a treatment called 177Lu-PSMA-617 for people with liver cancer (hepatocellular carcinoma or HCC) that has spread (metastatic) or cannot be removed by surgery. You may be able to join if you have liver cancer confirmed by a biopsy or imaging, and your cancer has spread or cannot be removed. You also need to have received at least one previous treatment for your cancer, including anti-PD-L1 therapy. Researchers want to see how many participants have at least 50% of their cancer spots (lesions) show up on a special scan (PSMA-Avid Lesions on PET Imaging) after 12 weeks. They will also track any side effects for 240 days to understand how safe the treatment is. This study plans to enroll 10 participants, but its current status is unclear.
- Study design
- This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 10 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be monitored for side effects for 240 days after treatment. The effectiveness of the treatment will be assessed at 12 weeks after the intervention.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
NCT06852820
68Ga-PSMA-11 PET-directed Radioligand Therapy in Metastatic Hepatocellular Carcinoma (HCC)
Recruiting
PHASE2Ages 18+InterventionalTreatmentMelissa LumishInvestigator-initiated
~10 participants
Updated 2026-05-08 on ClinicalTrials.gov
What's tested:Lu-PSMA-617
At a glance
Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percentage of Participants with PSMA-Avid Lesions on PET Imaging (≥50%)
Measured over 12 weeks post intervention
+1 more outcome measured
Conditions
Where it's being run
1 sites across 1 statesOhio1
Study leadership
- Melissa Lumish, MD · PRINCIPAL_INVESTIGATOR · Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Participants must have histologically, cytologically or radiographically confirmed hepatocellular carcinoma by LI-RADS30 with metastatic and/or unresectable disease.
Participants must have received one prior line of systemic therapy for the treatment of metastatic and/or unresectable HCC including anti-PD-L1 therapy. Participants will be enrolled at the time of progression on first-line therapy for metastatic and/or unresectable disease.
Age \>18 years. Because no dosing or adverse event data are currently available on the use of 177Lu-PSMA-617 (Lu-177 vipivotide tetraxetan) in participants \<18 years of age, children are excluded from this study.
ECOG performance status 0 or 1.
Participants must have normal organ and marrow function as defined below:
At least one target lesion measurable by RECIST 1.1 criteria.
PSMA-PET demonstrating PSMA PET positive lesion (higher uptake in the tumor compared with background liver uptake).
Participants must have the ability to understand and the willingness to sign a written informed consent document.
Participants of childbearing age are using an appropriate method of contraception.
Exclusion
Participants receiving any other investigational agents.
Subject has received investigational therapy within 4 weeks or within 5 half-lives of the therapeutic agent (whichever is shorter).
Ongoing grade 3 or higher toxicity from prior anticancer systemic therapy.
Prior treatment with Y90 radioembolization for hepatocellular carcinoma.
Participants who have undergone major surgery within 3 months of screening and have not adequately recovered.
Known additional malignancy that currently requires active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy.
Participants with untreated brain metastases and/or carcinomatous meningitis will be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events. Participants with previously treated brain metastases may participate provided they are stable without evidence of new or enlarging brain metastases and are not using steroids for at least 7 days prior to trial treatment.
Participants with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
Participants with known psychiatric or substance use disorders that would interfere with cooperation with the requirements of the trial, in the opinion of the treating investigator.
Subject is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 7 months for females and 14 weeks for males after the last dose of trial treatment. Pregnant or breastfeeding women are excluded from this study because 177Lu-PSMA-617 has not been previously studied in this population and the potential for teratogenic or abortifacient effects are unknown. Because there is an unknown but potential risk for adverse events in nursing infants secondary to the treatment of the mother with 177Lu-PSMA-617, breastfeeding should be discontinued if the mother is treated with 177Lu-PSMA-617. These potential risks may also apply to 68Ga-PSMA-11 used in this study.
Subject has received live vaccine within 30 days prior to the first dose of trial treatment.
Subject with recent variceal bleeding, gastrointestinal bleeding or high risk of bleeding.
What this trial measures
- Percentage of Participants with PSMA-Avid Lesions on PET Imaging (≥50%)12 weeks post intervention
Study is feasible if at least 1 PSMA-PET positive lesion is identified in at least 50% of the participants in this cohort
- Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]240 days post treatment